PURPOSE: The objective was to test whether tumor pH and (31)P magnetic resonance spectroscopic end points were related to treatment outcome in pet canine patients with spontaneous soft tissue sarcomas treated with thermoradiotherapy. EXPERIMENTAL DESIGN: Forty-two dogs with evaluable (31)P magnetic resonance spectroscopic end points and pH data were included in this study. Tumor variables (grade and volume), extracellular pH (pHe), T(2) relaxation times, intracellular pH, and selected phosphometabolite ratios were examined for correlation with clinical outcome. RESULTS: From 39 dogs, pHe was a predictor of metastasis-free survival (MFS), with hazard ratio (HR, 0.29; P = 0.005) and overall survival (OS) with (HR, 0.36; P = 0.013). Tumor volume (>19 cm(3)) was related to MFS (HR, 2.14; P = 0.04), time to local failure (HR, 3.4; P = 0.025), and OS (HR, 2.27; P = 0.03). There was no association between T(2) or intracellular pH and clinical outcome. Tumor grade (high versus low/intermediate) and phosphodiester/betaATP ratio were identified as significant predictors for MFS, with (HR, 2.66; P = 0.009) and (HR, 0.75; P = 0.027), respectively, and as predictors of OS with (HR, 2.66; P = 0.009) and (HR, 0.76; P = 0.03), respectively. The phosphodiester/phosphocreatinine ratio predicted time to local failure (HR, 1.24; P = 0.017). CONCLUSIONS: pHe was predictive of metastasis and OS in canine spontaneous sarcomas. To our knowledge, this is the first time that pHe has been shown to be predictive of clinical outcome. The results suggest that additional studies should be considered evaluating the prognostic significance of this variable. Phospholipid resonances, related to membrane metabolism, were related to clinical outcome, confirming recent results reported in human patients with soft tissue sarcomas treated with thermoradiotherapy.
PURPOSE: The objective was to test whether tumor pH and (31)P magnetic resonance spectroscopic end points were related to treatment outcome in pet caninepatients with spontaneous soft tissue sarcomas treated with thermoradiotherapy. EXPERIMENTAL DESIGN: Forty-two dogs with evaluable (31)P magnetic resonance spectroscopic end points and pH data were included in this study. Tumor variables (grade and volume), extracellular pH (pHe), T(2) relaxation times, intracellular pH, and selected phosphometabolite ratios were examined for correlation with clinical outcome. RESULTS: From 39 dogs, pHe was a predictor of metastasis-free survival (MFS), with hazard ratio (HR, 0.29; P = 0.005) and overall survival (OS) with (HR, 0.36; P = 0.013). Tumor volume (>19 cm(3)) was related to MFS (HR, 2.14; P = 0.04), time to local failure (HR, 3.4; P = 0.025), and OS (HR, 2.27; P = 0.03). There was no association between T(2) or intracellular pH and clinical outcome. Tumor grade (high versus low/intermediate) and phosphodiester/betaATP ratio were identified as significant predictors for MFS, with (HR, 2.66; P = 0.009) and (HR, 0.75; P = 0.027), respectively, and as predictors of OS with (HR, 2.66; P = 0.009) and (HR, 0.76; P = 0.03), respectively. The phosphodiester/phosphocreatinine ratio predicted time to local failure (HR, 1.24; P = 0.017). CONCLUSIONS:pHe was predictive of metastasis and OS in canine spontaneous sarcomas. To our knowledge, this is the first time that pHe has been shown to be predictive of clinical outcome. The results suggest that additional studies should be considered evaluating the prognostic significance of this variable. Phospholipid resonances, related to membrane metabolism, were related to clinical outcome, confirming recent results reported in humanpatients with soft tissue sarcomas treated with thermoradiotherapy.
Authors: Mark W Dewhirst; Donald E Thrall; Gregory Palmer; Thies Schroeder; Zeljko Vujaskovic; H Cecil Charles; James Macfall; Terence Wong Journal: Int J Hyperthermia Date: 2010 Impact factor: 3.914
Authors: Andrey A Bobko; Timothy D Eubank; Jeffrey L Voorhees; Olga V Efimova; Igor A Kirilyuk; Sergey Petryakov; Dmitrii G Trofimiov; Clay B Marsh; Jay L Zweier; Igor A Grigor'ev; Alexandre Samouilov; Valery V Khramtsov Journal: Magn Reson Med Date: 2011-11-23 Impact factor: 4.668
Authors: Valery V Khramtsov; George L Caia; Keerthi Shet; Eric Kesselring; Sergey Petryakov; Jay L Zweier; Alexandre Samouilov Journal: J Magn Reson Date: 2009-11-26 Impact factor: 2.229
Authors: Benjamin L Viglianti; Michael Lora-Michiels; Jeanie M Poulson; Lan Lan; Daohai Yu; Dahio Yu; Linda Sanders; Oana Craciunescu; Zeljko Vujaskovic; Donald E Thrall; James Macfall; Cecil H Charles; Terence Wong; Mark W Dewhirst Journal: Clin Cancer Res Date: 2009-07-21 Impact factor: 12.531
Authors: Yakov Y Woldman; Sergey V Semenov; Andrey A Bobko; Igor A Kirilyuk; Julya F Polienko; Maxim A Voinov; Elena G Bagryanskaya; Valery V Khramtsov Journal: Analyst Date: 2009-03-11 Impact factor: 4.616
Authors: Melissa N Loja; Zhen Luo; D Greg Farwell; Quang C Luu; Paul J Donald; Deborah Amott; Anh Q Truong; Regina F Gandour-Edwards; N Nitin Journal: Int J Cancer Date: 2012-10-11 Impact factor: 7.396
Authors: Matthew A McBrian; Iman Saramipoor Behbahan; Roberto Ferrari; Trent Su; Ta-Wei Huang; Kunwu Li; Candice S Hong; Heather R Christofk; Maria Vogelauer; David B Seligson; Siavash K Kurdistani Journal: Mol Cell Date: 2012-11-29 Impact factor: 17.970